A record of what Motilal Oswal Analysis said publicly, with the source. Not advice.
“Motilal Oswal is bullish on Symbiotec Pharmalab, with a target price of ₹1,430 against its current market price of ₹1,168, indicating a potential upside of 22%. Its EPS is projected to grow at a CAGR of 23% between FY26 and FY28E, while FY27E RoE is estimated at 10.4%.”
Motilal Oswal Analysis’s track record (trackable calls only): 453 graded calls · 95% CI 36–45%
Symbiotec PharmalabBullishCalled 03 Nov 2026Graded 21 Nov 2026
R4 TARGET_CALL: entered ₹1233.2 on 2026-11-04 (next trading session's close); target ₹1430 reached at close ₹1513.6 on 2026-11-06. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.
How it played out
How this is worked out- Time to target
- The target was reached on a close 2 trading sessions (2 calendar days) after the entry.
- Worst close against it
- No close was ever against the call before the target was reached. Closing prices only; an intraday dip is never counted.
From the entry the grade used, on closing prices. This is a record of one past call and is not advice.